收费全文 | 7221篇 |
免费 | 438篇 |
国内免费 | 57篇 |
耳鼻咽喉 | 63篇 |
儿科学 | 294篇 |
妇产科学 | 239篇 |
基础医学 | 761篇 |
口腔科学 | 153篇 |
临床医学 | 1248篇 |
内科学 | 1054篇 |
皮肤病学 | 78篇 |
神经病学 | 575篇 |
特种医学 | 221篇 |
外科学 | 695篇 |
综合类 | 79篇 |
一般理论 | 11篇 |
预防医学 | 1058篇 |
眼科学 | 99篇 |
药学 | 576篇 |
中国医学 | 13篇 |
肿瘤学 | 499篇 |
2023年 | 30篇 |
2022年 | 25篇 |
2021年 | 92篇 |
2020年 | 74篇 |
2019年 | 127篇 |
2018年 | 157篇 |
2017年 | 109篇 |
2016年 | 119篇 |
2015年 | 153篇 |
2014年 | 224篇 |
2013年 | 315篇 |
2012年 | 461篇 |
2011年 | 497篇 |
2010年 | 337篇 |
2009年 | 235篇 |
2008年 | 468篇 |
2007年 | 519篇 |
2006年 | 536篇 |
2005年 | 489篇 |
2004年 | 472篇 |
2003年 | 459篇 |
2002年 | 499篇 |
2001年 | 106篇 |
2000年 | 102篇 |
1999年 | 88篇 |
1998年 | 80篇 |
1997年 | 82篇 |
1996年 | 47篇 |
1995年 | 60篇 |
1994年 | 53篇 |
1993年 | 40篇 |
1992年 | 42篇 |
1991年 | 41篇 |
1990年 | 34篇 |
1989年 | 31篇 |
1988年 | 39篇 |
1987年 | 32篇 |
1986年 | 32篇 |
1985年 | 33篇 |
1984年 | 31篇 |
1983年 | 36篇 |
1982年 | 30篇 |
1981年 | 28篇 |
1980年 | 25篇 |
1979年 | 24篇 |
1978年 | 22篇 |
1977年 | 22篇 |
1976年 | 18篇 |
1974年 | 33篇 |
1971年 | 16篇 |
Purpose
Anorexia nervosa (AN) is a chronic and life-threatening eating disorder that can have a considerable negative impact on the growing skeleton. We hypothesized that the long-term impact on bone health may persist even after normalization of body weight.Methods
41 females (mean age 21.2 ± 2.9 years) with a history of adolescent-onset AN attended a follow-up bone health assessment at 5 years (T5, n?=?28) or 10 years (T10, n?=?13) after their first AN-related hospital admission. Assessment included dual-energy x-ray absorptiometry measurements of the total body, lumbar spine, and proximal femur, peripheral quantitative computed tomography at the radius and tibia, anthropometric measurements, serum biochemistry, fracture history, and a patient questionnaire.Results
A recovery in body weight and BMI was seen for both the T5 and T10 cohorts (BMI at intake 16.6, BMI at T5-T10 21.2-21.3). Dual-energy x-ray absorptiometry body composition indicated a recovery of fat mass and lean tissue mass. Total BMD was unaffected, but reductions were seen at the femoral neck and arms. Peripheral quantitative computed tomography showed reduced trabecular and cortical bone in the radius, and cortical thinning in the tibia. AN patients showed a statistically significant reduction in measures of radiographic bone health at follow up, although not to a degree that necessitated clinical intervention. Serum insulin-like growth factor 1 was also positively correlated with total BMD and BMC measures. While fracture risk was not increased, a subset of participants (8%) showed multiple (>4) fractures.Conclusion
A longitudinal study of adolescent AN showed persisting negative effects on bone health. 相似文献The purpose of this consensus guideline is to outline recommendations for genetic testing that medical professionals can use to assess hereditary risk for breast cancer.
MethodsLiterature review included large datasets, basic and clinical science publications, and recent updated national guidelines. Genetic testing to assess hereditary risk of cancer is a complex, broad, and dynamic area of medical research. The dominant focus of this guideline is limited in scope to breast cancer.
ResultsThere is a lack of consensus among experts regarding which genes among many should be tested in different clinical scenarios. There is also variation in the degree of consensus regarding the understanding of risk and appropriate clinical management of mutations in many genes.
ConclusionsGenetic testing should be made available to all patients with a personal history of breast cancer. Recent data are reviewed that support genetic testing being offered to each patient with breast cancer (newly diagnosed or with a personal history). If genetic testing is performed, such testing should include BRCA1/BRCA2 and PALB2, with other genes as appropriate for the clinical scenario and family history. For patients with newly diagnosed breast cancer, identification of a mutation may impact local treatment recommendations. Patients who had genetic testing previously may benefit from updated testing. Genetic testing should be made available to patients without a history of breast cancer who meet National Comprehensive Cancer Network guidelines. Finally, variants of uncertain significance are not clinically actionable and these patients should be managed based on their individual risk factors.
相似文献